DUBLIN, Ohio, Jan. 2, 2024  /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release second-quarter financial results for its fiscal year 2024 on February 1, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern.To access the webcast and corresponding slide presentation, visit Cardinal Health's Investor Relations page. No access code is required. Presentation slides and a webcast replay will be available on t ...

Cardinal Health, Inc. (NYSE:CAH) Q1 2024 Earnings Conference Call November 3, 2023 8:30 AM ET Company Participants Matt Sims - VP of IR Jason Hollar - CEO Aaron Alt - CFO Conference Call Participants Lisa Gill - JPMorgan Eric Percher - Nephron Research Kevin Caliendo - UBS Erin Wright - Morgan Stanley George Hill - Deutsche Bank Elizabeth Anderson - Evercore Daniel Grosslight - Citi Charles Rhyee - TD Cowen Allen Lutz - Bank of America Operator Good day, and welcome to today's First Quarter Financial Year 2 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 1-11373 Cardinal Health, Inc. (Exact name of registrant as specified in its charter) (State or other j ...

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_0dfd0b29486237e1091cb07603273918.html ...

Q4 FY23 Earnings Cardinal Health, Inc. August 15, 2023 ...

Financial Data and Key Metrics Changes - Cardinal Health reported a record financial performance for fiscal year 2023, achieving a non-GAAP EPS of $5.79, reflecting a 14% growth year-over-year [6][10] - The company generated $205 billion in revenue for fiscal 2023, a 13% increase compared to the previous year, with gross margin rising 5% to $6.9 billion [15][16] - Adjusted free cash flow reached $2.8 billion, with a strong cash position of $4 billion at year-end [17][18] Business Line Data and Key Metrics Changes - In the Pharma segment, revenue increased by 15% to $49.7 billion in Q4, with segment profit rising 12% to $504 million, driven by strong performance in generics and specialty products [10][11] - The Medical segment reported flat revenue of $3.8 billion in Q4 but achieved a profit of $82 million, a significant improvement from a loss in the prior year [12][13] - For the full year, Pharma segment profit increased 13% to $2 billion, while Medical segment profit decreased 49% to $111 million due to lower volumes and unfavorable sales mix [16] Market Data and Key Metrics Changes - The company noted broad-based strength in pharmaceutical demand across various product categories, including brand, specialty, consumer health, and generics [10][11] - The Medical segment experienced a decrease in products and distribution sales, partially offset by growth in at-home solutions [12] Company Strategy and Development Direction - Cardinal Health is focused on three strategic imperatives: enhancing the Pharma segment's resilience, executing the Medical Improvement Plan, and maximizing shareholder value [7][9] - The company is investing in its Nuclear & Precision Health Solutions business and has launched the Navista Network to support community oncologists [8][27] - Cardinal Health aims to achieve a 12% to 14% EPS growth CAGR from fiscal 2024 to 2026, building on a higher fiscal 2023 baseline [22][37] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate inflation and supply chain challenges, with expectations of improved profitability in fiscal 2024 [31][36] - The company anticipates continued growth in the Pharma segment, particularly from GLP-1 medications, while the Medical segment is expected to improve sequentially throughout the year [19][21] Other Important Information - Cardinal Health completed a merger with BlackRock's Transaction Data Systems, which is expected to accelerate future growth [9] - The company returned over $2.5 billion to shareholders, including a $500 million accelerated share repurchase program [18] Q&A Session Summary Question: Clarification on GLP-1 impact on revenue guidance - Management confirmed that the revenue guidance increase is primarily due to GLP-1 medications, which are lower margin but contribute to overall revenue growth [40] Question: Core performance metrics for Medical segment - Management clarified that the core performance for the Medical segment was approximately $60 million, with additional contributions from seasonality and one-time items [42][43] Question: Progress on Navista offering - Management highlighted that the Navista Network is being built on existing capabilities and is focused on supporting community oncologists, with new leadership and customer engagement initiatives in place [51][52] Question: Capital allocation priorities for fiscal 2024 - Management indicated a disciplined approach to capital allocation, focusing on organic growth investments, litigation payments, and shareholder returns [76]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 1-11373 Cardinal Health, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction o ...

Cardinal Health, Inc. (NYSE:CAH) Q3 2023 Earnings Conference Call May 4, 2023 8:30 AM ET Company Participants Kevin Moran - Vice President, Investor Relations Jason Hollar - Chief Executive Officer Aaron Alt - Chief Financial Officer Conference Call Participants Michael Cherny - Bank of America Lisa Gill - JPMorgan Kevin Caliendo - UBS Elizabeth Anderson - Evercore ISI Eric Percher - Nephron George Hill - Deutsche Bank Eric Coldwell - Baird Steven Valiquette - Barclays Daniel Grosslight - Citi Charles Rhyee ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 1-11373 Cardinal Health, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organ ...

Financial Data and Key Metrics Changes - Total company revenue increased by 13% and gross margin increased by 3%, driven primarily by the Pharmaceutical segment [11] - Operating earnings were $467 million, consistent with the previous year, reflecting growth in the Pharma segment profit offset by a decline in Medical segment profit [11] - Earnings per share (EPS) grew by 4% to $1.32, with a diluted weighted average share count of 263 million, down 6% year-over-year due to share repurchases [12] Business Line Data and Key Metrics Changes - **Pharmaceutical Segment**: Revenue increased by 15% to $48 billion, with segment profit rising by 9% to $464 million, driven by growth in branded and specialty pharmaceutical sales [13][14] - **Medical Segment**: Revenue decreased by 7% to $3.8 billion, with segment profit declining by 66% to $17 million, primarily due to lower product and distribution sales [16] Market Data and Key Metrics Changes - Strong overall pharmaceutical demand was noted, particularly from large customers, with contributions from new customers and seasonal products [14] - The Medical segment experienced volume softness, but there was a slight improvement in PPE volumes sequentially [17] Company Strategy and Development Direction - The company is focused on three strategic priorities: executing the medical improvement plan, enhancing the growth of the Pharmaceutical segment, and maximizing shareholder value [10][22] - Investments are being made in expanding the Cardinal Health brand portfolio and optimizing supply chain operations to mitigate inflation impacts [24][25] - The company plans to hold an Investor Day on June 8th to discuss long-term financial outlook and growth strategies [29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of the Pharmaceutical segment and anticipated gradual improvement in the Medical segment [21] - The company raised its EPS guidance for fiscal 2023, reflecting improved outlooks for the Pharmaceutical segment and interest income [18] - Management acknowledged ongoing inflationary pressures but noted effective mitigation actions, expecting to exit the year with at least 50% inflation mitigation [20][23] Other Important Information - The company completed a $1 billion accelerated share repurchase program and initiated a new $250 million program, with expectations of $1.5 billion to $2 billion in share repurchases for fiscal 2023 [12] - The company reported a cash position of $3.7 billion with no outstanding borrowings on its credit facility [13] Q&A Session All Questions and Answers Question: Expectations around surgical procedures and staffing issues - Management acknowledged constraints impacting growth in the Medical segment and anticipated gradual improvement in volumes as staffing issues resolve [32][33] Question: Pharma improvement and interest expense guidance - Management indicated that the improvement in the Pharma segment is primarily driven by volume, with interest expense guidance reflecting changes in cash balances rather than significant differences in interest rates [40][41][42] Question: Concerns or headwinds built into EPS guidance - Management provided a balanced outlook, noting that while the Pharma segment is expected to grow, the Medical segment has areas of concern that need to be monitored [45][47][56] Question: Opportunities in COVID treatments and core Pharma segment - Management noted limited participation in COVID treatments but indicated potential opportunities for 2024 and beyond as commercialization opens up [50][52] Question: Pricing and customer receptivity in Med/Surg - Management discussed a consistent approach to pricing adjustments and the desire to work collaboratively with customers to address challenges [61][62] Question: Size and growth of the at-home solutions business - Management confirmed that the at-home solutions business generated $2.4 billion in revenue last year, with approximately 9% growth in the first two quarters [68]